On May 14, 2025, the clinical trial project “Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ST-1898 Tablets in Patients with Inoperable Resectable or Metastatic Melanoma” was successfully initiated at Beijing GoBroad Hospital.
This collaboration with Prof. Guo Jun's team from Beijing Cancer Hospital at Beijing GoBroad Hospital is aimed at accelerating the extended clinical trial for melanoma indication, speeding up the enrollment of subjects, and making adequate preparation for the subsequent conduct of the pivotal registration clinical study. Mr. Zheng Xiaoyu, CEO of GoBroad Healthcare Group, and his team attended the launch meeting.
At the meeting, Prof. Guo Jun briefly summarized and fully affirmed the efficacy and safety data of ST-1898 in the preclinical study of melanoma indications. At the same time, Prof. Guo Jun also highly praised Beijing GoBroad Hospital for providing good treatment conditions and care for patients, which helped to improve patient compliance and better monitor adverse reactions, and greatly improved the efficiency of clinical studies. The next step will be to focus on pivotal clinical studies to further validate the safety and efficacy of the melanoma indication. As the first landmark clinical trial project initiated in the melanoma and sarcoma department of Beijing GoBroad Hospital, Mr. Zheng attaches great importance to the project and fully supports it, stating that he will continue to pay attention to the clinical progress of ST-1898, and expects that Beijing GoBroad Hospital can speed up the process of launching the project and bring new hope to more patients. Dr. Zhang Qiang, President and Chief Scientific Officer of Scitech Pharma, briefly introduced the AI drug discovery platform and the development history of ST-1898, and sincerely thanked the investigators and Beijing GoBroad Hospital for their full support. Mr. Wang Kexiu, Chairman of Scitech Pharma, looks forward to the opening of a broader strategic cooperation between the two parties around AI drug design and translational medicine, and to jointly promote the research and development of innovative oncology drugs in China for the benefit of more patients.
About ST-1898 Tablets
ST-1898 Tablet is a small molecule multi-target tyrosine kinase inhibitor independently developed by Scitech Pharma through its proprietary AI drug design platform (SigmaHit®) with global intellectual property rights, capable of inhibiting c-MET, VEGFR-2, PDGFRa, RET, c-KIT, TRK-A, TRK-B, AXL and other targets, which was approved by the National Medical Products Administration (NMPA) in July 2020 to conduct clinical trials. In the Phase I clinical trial, ST-1898 tablets have demonstrated good safety and preliminary efficacy in a variety of tumors, including liver, lung, thyroid, gallbladder and intestinal cancers.
Currently, Phase II melanoma and Phase II advanced renal cell carcinoma clinical trials are being conducted simultaneously at Beijing Cancer Hospital with significant efficacy and excellent safety observed, in which it meets the original intention of drug design. The initiation of this clinical trial for thyroid cancer signifies the therapeutic potential of ST-1898 tablets for a wide range of indications and broad application prospects.
According to the existing clinical data, ST-1898 tablets have demonstrated good anti-tumor properties and safety in multiple tumors (kidney cancer, melanoma, thyroid cancer), laying a solid foundation for the expansion of indications and clinical trials in the next phase.
About Beijing GoBroad Hospital
Beijing GoBroad Hospital is a research-driven institution dedicated to the diagnosis and treatment of complex diseases, clinical research, and the industrial translation of biopharmaceuticals and medical devices. As a key public service platform for clinical research in Beijing, the hospital brings together China’s leading clinical research experts and a comprehensive support team. By leveraging its strong clinical research capabilities, Beijing GoBroad integrates the city’s extensive resources in basic research, startup enterprises, and scientific institutions to build a high-level ecosystem for medical innovation.
Scitech Pharma
